Department of Radiology, Okan University Hospital, Aydınlı Cad 2, İstanbul, Tuzla 34947, Turkey.
AJR Am J Roentgenol. 2020 Sep;215(3):753-759. doi: 10.2214/AJR.19.21897. Epub 2020 May 14.
Metallic stenting of malignant biliary strictures is the preferred method of palliation, because most patients present when the condition is inoperable. Most metallic stents, however, are occluded 6-8 months after deployment. Intraductal radiofrequency ablation has been used in previous studies to improve stent patency. The purpose of this study was to assess a single-center experience with percutaneous intraductal microwave ablation of malignant biliary strictures. In this retrospective case series study, data on 12 patients with malignant biliary obstruction who underwent percutaneous intraductal microwave ablation followed by metallic stenting were evaluated. Ablation procedures were performed with generator frequencies of 902-928 MHz, power set at 6-10 W, and ablation time of 60-90 seconds in a temperature-controlled manner with target temperature set at 80°C. Causes of malignant biliary obstruction were pancreatic carcinoma in four patients, gastric antrum carcinoma in three, cholangiocarcinoma in two, metastasis in two, and gallbladder carcinoma in one patient. Percutaneous intraductal microwave ablation and metallic stenting were performed successfully in all patients. There was no procedural mortality or major complication. The most common minor complication was abdominal pain. Biliary decompression was achieved in all patients at the end of the first month. The mean follow-up time was 9.4 months. The median primary stent patency period was 231 days. There were two stent occlusions due to sludge formation, and two patients died during follow-up. Percutaneous intraductal microwave ablation of malignant biliary strictures is safe and feasible. Prospective randomized controlled studies with long-term results are warranted to determine the effectiveness of this technique in lengthening the stent patency period.
单中心经验回顾性研究
经皮胆管内微波消融治疗恶性胆管狭窄是一种姑息性治疗方法,因为大多数患者在病情无法手术时就诊。然而,大多数金属支架在放置后 6-8 个月会被堵塞。腔内射频消融术已在前瞻性研究中用于改善支架通畅率。本研究旨在评估单中心经皮胆管内微波消融治疗恶性胆管狭窄的经验。
在这项回顾性病例系列研究中,评估了 12 例接受经皮胆管内微波消融联合金属支架置入治疗的恶性胆管梗阻患者的数据。消融程序使用 902-928 MHz 的发生器频率、6-10 W 的功率、60-90 秒的消融时间和 80°C 的目标温度进行温度控制。
引起恶性胆管梗阻的原因包括 4 例胰腺癌、3 例胃窦癌、2 例胆管癌、2 例转移癌和 1 例胆囊癌。所有患者均成功进行了经皮胆管内微波消融和金属支架置入。无手术相关死亡或重大并发症。最常见的轻微并发症是腹痛。所有患者在第一个月结束时均实现了胆道减压。平均随访时间为 9.4 个月。中位初次支架通畅时间为 231 天。由于胆泥形成,发生了 2 例支架堵塞,2 例患者在随访期间死亡。
经皮胆管内微波消融治疗恶性胆管狭窄是安全可行的。需要进行前瞻性随机对照研究以确定该技术在延长支架通畅时间方面的有效性。